The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication appears to deliver notable improvements in weight loss compared to previous therapies. Initial patient studies have indicated significant reductions in body mass , conceivably